CLOSEOUT LETTER
Thermavis MARCS-CMS 613564 —
- Product:
- Medical Devices
- Recipient:
-
Recipient NameMark Norman Nightingale
- Thermavis
19 Heather Park Drive
London, England
HA0 1SS
United Kingdom-
- markn@transputec.com
- Issuing Office:
- Center for Devices and Radiological Health
United States
United States
Dear Mark Norman Nightingale:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter CMS# 613564, dated March 4, 2021. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Michael J. Hoffmann
Director
Office of Health Technologies 3 - Gastrorenal, ObGyn,
General Hospital, and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health